Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A registry study affirmed that insulin glargine (Lantus) didn't significantly raise cancer risk compared with "human" insulin....
John Buse, MD, PhD, of the University of North Carolina at Chapel Hill, and colleagues found that, new insulin glargine users had a nonsignificant 12% higher incidence of cancer compared with those starting human neutral protamine Hagedorn (NPH) insulin when followed about a year.
The results were likewise nonsignificant for breast, prostate, and colon cancers specifically, the group reported online in Diabetes Care.
http://www.diabetesincontrol.com/articles/diabetes-news/14968-glargine-does-not-increase-cancer-risk
John Buse, MD, PhD, of the University of North Carolina at Chapel Hill, and colleagues found that, new insulin glargine users had a nonsignificant 12% higher incidence of cancer compared with those starting human neutral protamine Hagedorn (NPH) insulin when followed about a year.
The results were likewise nonsignificant for breast, prostate, and colon cancers specifically, the group reported online in Diabetes Care.
http://www.diabetesincontrol.com/articles/diabetes-news/14968-glargine-does-not-increase-cancer-risk